nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-2549DB1C·Framework v5.9·Pipeline v0.4·Evaluated 22 Sept 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Narrative review

Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment.

Zuraw et al.Zuraw, Bork, Bouillet et al.·2025·Clinical reviews in allergy & immunology·10.1007/s12016-025-09027-4 ↗

Primary claim

HAE-nC1INH patients are at risk of serious morbidity and mortality.

Supported · clinical reports support serious airway risk, although the evidence base is observational and subtype-specific
In brief

An actionable international consensus updates HAE-nC1INH diagnosis and treatment, but uncontrolled and uneven evidence limits confidence in subtype-specific recommendations.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

Hereditary angioedema (HAE) has been recognized for almost 150 years. The newest form of HAE, where C1 inhibitor levels are normal (HAE-nC1INH), was first described in 2000. Over the last two decades, new types of apparent non-mast cell-mediated angioedema with normal quantity and activity of C1INH have been described, in some cases with proven genetic pathogenic variants that co-segregate with angioedema expression within families. Like HAE due to C1INH deficiency, HAE-nC1INH patients are at risk of serious morbidity and mortality. Therefore, proactive management and treatment of HAE-nC1INH patients after an expert physician diagnosis is critically important. The underlying pathophysiology responsible for the angioedema has also been clarified in some of the HAE-nC1INH types. While several clinical guidelines and practice parameters including HAE-nC1INH have been published, we have made substantial progress in our understanding encompassing diagnostic criteria, pathophysiology, and treatment outcomes. HAE International (HAEi) and the US HAE Association (HAEA) convened a symposium of global HAE-nC1INH experts to synthesize our current knowledge in the area. Given the paucity of high-level evidence in HAE-nC1INH, all recommendations are based on expert opinion. This review and expert opinion on the best practice approach to diagnosing and treating HAE-nC1INH will support physicians to better manage patients with HAE-nC1INH.

Key Claims

Primary finding · Supported

HAE-nC1INH patients are at risk of serious morbidity and mortality.

clinical reports support serious airway risk, although the evidence base is observational and subtype-specific

Abstract
Quote verified
Secondary · Tentative

Plasma-derived C1INH and icatibant are both broadly used and effective ODTs in HAE-XII, HAE-PLG, and HAE-UNK.

uncontrolled expert ratings and heterogeneous subtype samples limit efficacy inference

Section 3, Further Real-World Studies and Clinical Trials
Quote verified
Secondary · Tentative

LTP with progestin may be considered for HAE-FXII patients.

the recommendation rests on case series and uncontrolled survey ratings from a small sample

Section 3, Further Real-World Studies and Clinical Trials
Quote verified
Secondary · Tentative

Even without an identified mutation, a presumptive diagnosis of HAE-nC1INH made by an expert physician is sufficient.

expert consensus supports the recommendation amid absent validated biomarkers and continuing diagnostic uncertainty

Conclusion and Forward-Looking Statement
Quote verified
Secondary · Tentative

Lanadelumab may be considered as an option for LTP in HAE-FXII and HAE-UNK, and it may help some patients with HAE-PLG.

small uncontrolled samples include mixed responses and worsening in HAE-PLG

Section 3, Further Real-World Studies and Clinical Trials
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Operational eight-step diagnostic pathway

Figure 1 and the accompanying numbered steps turn a complex differential diagnosis into a clinical sequence covering documentation, C1INH testing, medication causes, mast-cell therapy, genetics, treatment response, and family screening.

↳ Section 1, Figure 1 and Diagnostic Algorithm Steps 1–8

#contribution

Substantive international treatment dataset

The HCT survey aggregates expert-reported outcomes for 594 patients from 15 countries, adding subtype-specific treatment information to a sparse literature.

↳ Section 3, HCT survey; Figures 2–4

#positioning

Evidence limitations shape recommendations

The paper withholds recommendations where short-term prophylaxis evidence is insufficient and declines to recommend attenuated androgens because benefit is inconsistent and harms are known.

↳ Section 3, Further Real-World Studies and Clinical Trials

Limitations

#methodological rigour

Literature selection method remains undescribed

The Introduction explains the symposium and revision process but not how studies were searched for, selected, or evaluated, limiting assessment of completeness and balance.

↳ Introduction

#application pathway

Subtype samples are highly uneven

Treatment conclusions range from substantial HAE-FXII and HAE-UNK groups to one- or two-patient observations and no reported outcomes for some subtypes, sharply limiting generalization.

↳ Section 3, HCT survey; Figures 2–4

#positioning

Survey precision exceeds evidentiary stability

Exact efficacy percentages are sometimes calculated from very small, expert-rated samples, while the survey instrument and detailed administration methods are deferred to an unavailable supplement.

↳ Section 3, HCT survey and Figures 2–4

Does this match your read? Add your assessment ↓

Nabu Commentary

The paper earns its strongest marks for an explicit clinical pathway, disciplined organization, and clear acknowledgment that recommendations are based on expert opinion. The HCT survey adds useful international treatment observations, but its subtype samples are highly uneven and its outcomes are retrospective expert ratings rather than controlled efficacy estimates. Contextualization is generally responsible because insufficient or inconsistent evidence sometimes leads directly to withheld recommendations. The principal craft limitation is that the symposium process is described while the literature-identification and selection process is not.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.5±0.1

Contribution
3.6

The paper meaningfully updates prior guidance by integrating recent genetic subtypes, an operational diagnostic algorithm, and an international treatment survey. The advance is clinically useful but remains incremental and descriptive.

Introduction; Section 1, Figure 1 and Table 1; Section 3, HCT survey

This survey provided information on 594 patients with HAE-nC1INH from 15 countries.

Methodological Rigour
3.4

The synthesis proceeds coherently from classification through diagnosis, mechanisms, biomarkers, and treatment, and it presents mixed findings rather than only favorable evidence. It does not describe how the literature was identified, selected, or adjudicated.

Introduction; Sections 1–3; Section 3, HAE-PLG treatment results

Given the paucity of high-level evidence, all recommendations in this paper are based on expert opinion.

Reporting
3.9

Numbered diagnostic steps, subtype headings, tables, and explicit evidence qualifiers make the argument navigable. Dense subtype detail and occasional broad framing modestly reduce precision without changing the article's overall message.

Section 1, Figure 1 and Diagnostic Algorithm; Abstract; Section 3

There are no data from controlled clinical trials.

Positioning
3.6

The paper situates its recommendations against prior guidelines and repeatedly identifies diagnostic, biomarker, and treatment uncertainties. Several limitations alter recommendations directly, although the small and uneven survey denominators are not consistently traced into every subtype-specific suggestion.

Introduction; Section 1, Limitations of the Clinical Characteristics; Section 3, Further Real-World Studies

Information regarding STP outcomes in HAE-nC1INH is insufficient... to provide treatment recommendations.

Lower confidence on Methodological Rigour, Positioning — domain match limited.

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The article is internally consistent overall, but precise treatment-response percentages may convey more stability than very small subtype denominators support. No statistical impossibility or contradiction was identified.

Research ConductNoted

No demonstrated distortion or other substantive conduct problem appears in the supplied text. A conflict-of-interest disclosure is absent despite organisational sponsorship and extensive discussion of commercial therapies; detailed survey materials in the unavailable supplement remain an assessability gap.

Flags: 0 declared / 5 total

Reference IntegrityClean

140 of 140 checkable references verified

140 references in manuscript citation details diverge from the cited records for 1 reference

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Skin · Other skin and subcutaneous diseases
Type of advanceSynthesis
Route to useNamed
AdvanceConsolidates
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

All recommendations rest on expert opinion, case reports, and small case series with no controlled trials or validated biomarkers, so nothing beyond observational description supports the primary claim.

From the paper
“This review and expert opinion on the best practice approach to diagnosing and treating HAE-nC1INH will support physicians to better manage patients with HAE-nC1INH.”

The paper explicitly names physicians as the actors who would use its diagnostic algorithm and treatment recommendations to manage HAE-nC1INH patients.

Pathway

Expert physicians, allergists and immunologists apply the consensus diagnostic algorithm and treatment guidance to identify and proactively manage HAE-nC1INH patients.

Barrier

Diagnosis lacks validated biomarkers and often relies on genetic testing that many clinicians cannot access, and treatment recommendations are unsupported by controlled trial evidence.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  2. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats
  3. CRISPR-Based Therapy for Hereditary Angioedema

    Cohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine

    Primary claim

    NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.

    Tentative
    Evidence Score
    3.6±0.1
    Reliability
    Caveats

How the rubric works →